Current role of positron emission tomography in thoracic oncology

Thorax

Volumn 53, Issue 8, 1998, Pages 703-712

  Lowe, Val J ^a   Naunheim, Keith S ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LUNG CANCER; LUNG SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 0031824299     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.8.703     Document Type: Review

References (76)

1. Warburg O. The metabolism of tumors. New York: Richard R Smith, 1931: 129-69.
2. Weber G. Enzymology of cancer cells. Part I. N Engl J Med 1977;296:468-92.
3. Weber G. Enzymology of cancer cells. Part II. N Engl J Med 1977;296:541-51.
4. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-9.
5. 18F) 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-61.
6. Duhaylongsod FG, Lowe VJ, Patz EJ, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52.
7. Langen KJ, Braun U, Rota KE, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993;34:355-9.
8. Torizuka T, Clavo AC, Wahl RL. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med 1997;38:382-6.
9. Lowe VJ, DeLong DM, Hoffman JM, et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-7.
10. Gurney JW. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. Radiology 1993;186:405-13.
11. Gurney JW, Lyddon DM, McKay JA. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. Radiology 1993;186: 415-22.
12. Schenk DA, Bryan CL, Bower JH, et al. Transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma. Chest 1987;92:83-5.
13. Salathe M, Soler M, Bolliger CT, et al. Transbronchial needle aspiration in routine fiberoptic bronchoscopy. Respiration 1992;59:5-8.
14. Wang KP, Kelly SJ, Britt JE. Percutaneous needle aspiration biopsy of chest lesions. New instrument and new technique. Chest 1988;93:993-7.
15. Polak J, Kubik A. Percutaneous thin needle biopsy of malignant and nonmalignant thoracic lesions. Radiol Diagn 1989;30:177-82.
16. Winning AJ, McIvor J, Seed WA, et al. Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions. Thorax 1986;41:875-9.
17. Daly BD, Faling LJ, Diehl JT, et al. Computed tomographyguided minithoracotomy for the resection of small peripheral pulmonary nodules. Ann Thorac Surg 1991;51:465-9.
18. Williams AJ, Santiago S, Lehrman S, et al. Transcutaneous needle aspiration of solitary pulmonary masses: how many passes? Am Rev Respir Dis 1987;136:452-4.
19. Mack MJ, Hazelrigg SR, Landreneau RJ, et al. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thor Surg 1993;56:825-30.
20. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997-1002.
21. Patz EJ, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90.
22. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410-4.
23. Duhaylongsod FG, Lowe VJ, Patz EJ, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9.
24. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET (see comments). J Nucl Med 1996;37:943-8.
25. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982-8.
26. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
27. Lowe VJ, Duhaylongsod FG, Patz EF, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997;202:435-9.
28. Lowe VJ, Fletcher J W, Gobar L, et al. Prospective investigation of PET in lung nodules. J Clin Oncol 1998;16:1075-84.
29. Higashi K, Seki H, Taniguchi M, et al. Bronchioloalveolar carcinoma: false-negative results on FDG-PET J Nucl Med 1997;38:79P.
30. Dewan NA, Reeb SD, Gupta NC, et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441-6.
31. Chin RJ, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Care Care Med 1995;152:2090-6.
32. Patz EJ, Lowe VJ, Goodman PC, et al. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617-21.
33. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Ear J Nucl Med 1996;23:741-7.
34. Sazon DA, Santiago SM, Soo HG, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.
35. Scott WJ, Gobar LS, Terry JD, et al. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-8.
36. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-6.
37. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-81.
38. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
39. Gdeedo A, Van SP, Corthouts B, et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 1997;10: 1547-51.
40. Patterson GA, Ginsberg RJ, Poon PY, et al. A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 1987;94:679-84.
41. Van Schil PE, Van HRH, Schoofs EL. The value of mediastinoscopy in preoperative staging of bronchogenic carcinoma. J Thorac Cardiovasc Surg 1989;97:240-4.
42. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23.
43. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705-13.
44. Wittens CH, Bollen EC, van DC, et al. Accuracy of computed tomography of the mediastinum in bronchogenic carcinoma. Netherlands J Surg 1991;43:240-4.
45. Whittlesey D. Prospective computed tomographic scanning in the staging of bronchogenic cancer. J Thorac Cardiovasc Surg 1988;95:876-82.
46. Bury T, Dowlati A, Paulus P, et al. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 1996;23:204-6.
47. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344: 1265-6.
48. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR 1996;166:531-6.
49. Schwartz LH, Panicek DM, Doyle MV, et al. Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. AJR 1997;168:1575-8.
50. Linos DA, Stylopoulos N. How accurate is computed tomography in predicting the real size of adrenal tumors? A retrospective study. Arch Surg 1997;132:740-3.
51. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-n-glucose. Radiology 1995; 194:131-4.
52. Maurea S, Mainolfi C, Wang H, et al. Positron emission tomography (PET) with fludeoxyglucose F-18 in the study of adrenal masses: comparison of benign and malignant lesions. Radiol Med 1996;92:782-7.
53. Erasmus JJ, Patz EJ, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogeinc carcinoma using 18F-fluorodeoxyglucose positron emission tomography (see comments). AJR 1997;168:1357-60.
54. Recine D, Rowland K, Reddy S, et al. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer 1990;66:2270-8.
55. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-60.
56. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-21.
57. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995;32:1495-512.
58. Patz EJ, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-82.
59. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET J Nucl Med 1995;36: 788-93.
60. Adler LP, Crowe JP, al KN, et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-50.
61. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204-9.
62. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588-93.
63. Liu RS, Yeh SH, Huang MH, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med 1995;22:1402-7.
64. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer 1996;73:882-6.
65. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-6.
66. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522-7.
67. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-92.
68. Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476-9.
69. Kole AC, Nieweg OE, van GR, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol 1997;4:57-63.
70. Nieweg OE, Pruim J, van GR, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-61.
71. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-70.
72. Boni R. Whole-body positron emission tomography: an accurate staging modality for metastatic melanoma. Arch Dermatol 1996;132:833-4.
73. Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
74. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
75. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR 1997;168:417-24.
76. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997;64:765-9.